Search Results 7291-7300 of 25223 for oral

  1. Hematology - Clinical trials

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  2. Clinical trials - Oncology (Medical)

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  3. Publications - Gerardo Colon-Otero, M.D. - Mayo Clinic

    Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome. Clin Endocrinol ...

  4. Cirrhosis Clinical Trials - Mayo Clinic Research

    In addition, various exploratory markers of effectiveness will be analyzed. A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in ...

  5. Dermatitis - Symptoms and causes - Mayo Clinic

    Howland: If those self-care steps don't help, your dermatologist may prescribe topical or oral medications, or other therapies. For Mayo Clinic News Network ...

  6. MONDAY HOUSECALL - Snoring Solutions, Fainting First Aid, Healthy Aging Tips and more

    Living with cancer: Oral chemotherapy — Not just any ordinary pill. Health Digest Triple X syndrome · Tricuspid atresia · Pemphigus · Fecal incontinence

  7. Rhabdomyosarcoma - Doctors and departments - Mayo Clinic

    ... Oral and throat cancer, Adenocarcinoma, Tongue base cancer, Oropharyngeal cancer. Show more areas of focus for Eric J. Moore, M.D.. Pagination Doctor search.

  8. A Study of BHV-3241 in Subjects with Multiple System Atrophy - Mayo Clinic

    and one other method that could include hormonal contraceptives (e.g., oral contraceptives, injectable contraceptives, contraceptive implant, patch) used for at ...

  9. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer - Mayo Clinic

    Subjects who have received a live/attenuated vaccine within 30 days of randomization (e.g., varicella, zoster, yellow fever, rotavirus, oral polio and measles, ...

  10. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    Therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin [LMWH], or novel oral anticoagulants) must be discontinued and coagulation ...